Adaptogenics Health Corp. (CSE: ADPT; OTCQB: ADPGF) has submitted formal comments to the U.S. Department of Health and Human Services calling for stronger quality controls in peptide compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The Vancouver-based life sciences company filed its submission to Docket No. HHS-OASH-2026-0496, targeting a specific vulnerability in peptide supply chains: certificates of analysis that may appear legitimate but cannot be independently verified. Investors may be watching how the company's regulatory engagement shapes its broader peptide research and development strategy.
Key Points
- Adaptogenics Health Corp. (CSE: ADPT; OTCQB: ADPGF) submitted formal comments to HHS on peptide compounding enforcement policy.
- The company recommends three controls: authenticating certificates of analysis at source, matching certificates to received batches, and independent laboratory testing of critical quality attributes.
- Comments were filed to Docket No. HHS-OASH-2026-0496; no financial figures were disclosed in the announcement.
- Investors may watch how HHS responds to industry submissions and how Adaptogenics applies these principles within its CLEAR Method quality framework.
Adaptogenics Identifies Certificate of Analysis Fraud Risk in Peptide Supply Chains
At the core of Adaptogenics' HHS submission is a focused concern: a certificate of analysis can carry the name of a legitimate manufacturer or laboratory and still be counterfeit, altered, or unrelated to the actual material received. The company argues that document appearance alone provides little assurance unless pharmacies can confirm who issued the certificate and whether it applies to the specific batch in hand. Adaptogenics recommends verifying certificates directly with the original manufacturer or testing laboratory through a trusted channel, reconciling lot identifiers, and maintaining records that trace material from manufacturer to receiving pharmacy.
Three-Point Framework Adaptogenics Presented to HHS Regulators
Adaptogenics structured its docket submission around three distinct controls it urged HHS to formalise. First, pharmacies should authenticate certificates at the source by verifying them directly with the issuing manufacturer or laboratory. Second, certificates must be reconciled against lot identifiers to confirm the document applies to the specific batch received. Third, qualified independent laboratories should test received materials against defined specifications for identity, purity, and other attributes relevant to intended use. The release states CEO Dr. J. David Warren described document authentication and laboratory testing as addressing different risks that together strengthen batch acceptance decisions.
How the HHS Submission Connects to Adaptogenics' CLEAR Method Strategy
Adaptogenics disclosed that the same quality principles informing its HHS submission also underpin the company's CLEAR Method, an internal quality framework being developed around manufacturer qualification, certificate verification, independent testing, and batch traceability. The company states it intends to apply these principles to its peptide research and development initiatives, including evaluation of delivery technologies. Adaptogenics also indicated plans to develop resources for healthcare providers summarising available evidence on dosing, administration, and monitoring, including areas where evidence remains limited.




Please wait processing your request...